Patients first,
Faster access,
Healthier lives
Global Regulatory Partners Japan (GRP Japan) is a pharmaceutical company helping international life science companies bring products to Japanese patients quickly and safely.
About Us
GRP Japan is a pharmaceutical company helping to bring international medical solutions to Japanese patients quickly and safely. Many medical treatments and drugs available overseas take time to reach patients in Japan.
Our Japan expertise and global network make GRP Japan the vital link between international innovation and local patient care. We’re committed to ensuring patients and medical professionals across Japan have access to the treatments and solutions that improve lives.
For companies seeking to bring healthcare solutions into Japan or other countries, see our Industry Solutions.
Our Products
At GRP Japan, our product portfolio centers on areas where new solutions can make the greatest impact:
• Innovative medicines
• Diabetes
• Biosimilars
• High-risk medical products
By focusing on these therapeutic areas, we help ensure Japanese patients gain timely access to breakthrough therapies and technologies from around the world.
Product Lineup
Baqsimi Nasal Powder
Latest News
Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan
Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.- SEE ALL
